Phaseline

Companies › Rottapharm Biotech

Rottapharm Biotech: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Balstilimab (AGEN2034)
Programmed cell death protein 1 antagonist
PDCD1Phase 1Refractory Metastatic Colorectal CancerDec 2026
Vorbipiprant (CR6086)
Prostanoid EP4 receptor antagonist
PTGER4Phase 1Refractory Metastatic Colorectal CancerDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05205330Vorbipiprant (CR6086)Phase 1Refractory Metastatic Colorectal CancerOncologyDec 2026
NCT05205330Balstilimab (AGEN2034)Phase 1Refractory Metastatic Colorectal CancerOncologyDec 2026

Targets

PTGER4 (1) PDCD1 (1)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech AstraZeneca Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical Mabwell (Shanghai) Bioscience Johnson & Johnson (Janssen)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.